Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is projected to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($1.96) per share and revenue of $12.0590 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $27.70 on Thursday. The firm has a 50-day simple moving average of $27.49 and a two-hundred day simple moving average of $34.63. The stock has a market cap of $1.62 billion, a PE ratio of -3.96 and a beta of 0.91. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Bank of America upped their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Leerink Partners upped their target price on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Royal Bank Of Canada lowered Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $57.00 to $28.00 in a research report on Wednesday, November 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, December 29th. Finally, Zacks Research upgraded Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $39.44.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 18,703 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $506,664.27. Following the sale, the chief executive officer owned 136,583 shares of the company’s stock, valued at approximately $3,700,033.47. This trade represents a 12.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James William Burns sold 2,932 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider owned 31,718 shares in the company, valued at $859,240.62. This represents a 8.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 33,503 shares of company stock worth $910,745. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. purchased a new position in Agios Pharmaceuticals during the 3rd quarter worth approximately $242,000. CANADA LIFE ASSURANCE Co grew its position in Agios Pharmaceuticals by 3.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 662 shares during the last quarter. TCG Crossover Management LLC boosted its stake in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after buying an additional 733,038 shares during the period. Alyeska Investment Group L.P. acquired a new position in Agios Pharmaceuticals in the 3rd quarter valued at about $5,881,000. Finally, Voleon Capital Management LP acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth approximately $268,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.